SYNGENE INTERNATIONAL share price has zoomed 3% and is presently trading at Rs 746.0.
Meanwhile, the BSE HEALTHCARE index is at 38,574.3 (up 0.3%).
Among the top gainers in the BSE HEALTHCARE index today are Pfizer (up 6.3%) and KIMS (up 3.1%).
HIKAL CHEMIC (down 2.8%) and ASTRAZENECA PHARMA (down 2.5%) are among the top losers today.
Over the last one year, SYNGENE INTERNATIONAL has moved down from Rs 756.6 to Rs 746.0, registering a loss of Rs 10.6 (down 1.4%).
On the other hand, the BSE HEALTHCARE index has moved up from 25,922.2 to 38,574.3, registering a gain of 48.8% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Glenmark Pharma (up 108.1%), Cadila Healthcare (up 104.7%) and Lupin (up 102.2%).
Dear Reader: If You Invest in Midcap Stocks, this is for You
The BSE Sensex is at 79,924.8 (down 0.5%).
The top losers among the BSE Sensex today are M&M (down 6.7%) and Tata Steel (down 2.1%). The most traded stocks in the BSE Sensex are Tata Steel and ITC.
In the meantime, NSE Nifty is at 24,312.4 (down 0.5%). M&M and Hindalco are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,344.2 to 79,924.8, registering a gain of 14,580.6 points (up 22.3%).
SYNGENE INTERNATIONAL net profit grew 5.5% YoY to Rs 1,886 million for the quarter ended March 2024, compared to a profit of Rs 1,787 million a year ago. Net sales declined 7.8% to Rs 9,169 million during the period as against Rs 9,944 million in January-March 2023.
For the year ended March 2024, SYNGENE INTERNATIONAL reported 9.8% increase in net profit to Rs 5,100 million compared to net profit of Rs 4,644 million during FY23. Revenue of the company grew 9.3% to Rs 34,886 million during FY24.
The current Price to earnings ratio of SYNGENE INTERNATIONAL, based on rolling 12 month earnings, stands at 58.9.
Equitymaster requests your view! Post a comment on "SYNGENE INTERNATIONAL Gains 3%; BSE HEALTHCARE Index Up 0.3%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!